

ASX Release

Suda Presentation

Stephen Carter, Executive Chairman for Suda Ltd, is currently meeting with brokers, carrying out a road show in Perth, Sydney and Melbourne.

A copy of the presentation follows.



Further information:
STEPHEN CARTER
EXECUTIVE CHAIRMAN
SUDA LTD

Tel: +61 8 6142 5555

sjcarter@sudaltd.com.au

SUDA LTD

Stephen Carter
Executive Chairman /CEO

SUDA LTD

- SUDA Ltd (ASX:SUD) is an Australian Drug Delivery company focused on oro-mucosal delivery of existing drugs using our novel delivery technology (SUDAMist™). The acquisition of NovaMist™ technology complements this model and provides a pipeline of products in various stages of development. This acquisition assists SUDA in its goal to become a major player in oro-mucosal products.

ArTiMist™

- Our lead product ArTiMist™, a sub-lingual artemether based malaria treatment, has been developed specifically for children with complicated malaria.
- In 2011 Thompson Reuters identified ArTiMist™ as one of the worlds 5 most promising drugs in Phase III clinical development.
- Successfully completed ArTiMist™ Phase III clinical trial in Children in Severe or complicated Malaria.





ArTiMist™

- Phase III Results

- 151 patients in 3 sites in Africa (Rwanda, Ghana and Burkina Faso)
- Sub-lingual ArTiMist™ superior to i.v. quinine
- 95.6% of ArTiMist™ patients had reduced parasite counts by >90% in the first 24 hours compared with only 40.6% using intravenous (i.v.) quinine
- Parasite clearance time 30 hours with ArTiMist™ vs. 68 hours with i.v. Quinine
- No Early treatment failures in the Artimist™ arm 10 in quinine arm.
- Results support that ArTiMist™ is an superior treatment for children with malaria
- Results provide a compelling argument for the potential use of ArTiMist™ as an early interventional treatment for children

ArTiMist™

- Advantages of ArTiMist™ over other treatments are:
 - It does not require hospitalisation or medically trained personnel for administration;
 - Not affected by GI complications;
 - By-passes the Liver and the significant metabolism seen from the first pass effect;
 - Does not require fatty diet for maximum effect;
 - Rapidly absorbed;
 - Can be administered to comatose patients;
 - Negates risk of infection from needle use;
 - Has a long shelf life; and
 - Critically, in hot climates, does not require cold chain storage

ArTiMist™

Next Steps

- Final Report due July 2013
- Discussions with potential trade sale partners
- Finalise the Regulatory documents Dec 2013
- Filing of Regulatory documents Jan 2014
- Trade sale

ArTiMist™

Value Proposition

- Phase III trials confirm superiority of ArTiMist™ over gold standard i.v. quinine.
- Successful commercial scale manufacture program completed.
- Drafting of Regulatory documentation advanced.
- Turn key trade sale of asset proposed.
- Massive un–met medical need.

NovaMist™

- SUDA has signed a Sale and Purchase Agreement to purchase the NovaMist™ IP and inventory.
- The agreement is subject to Novadel shareholder approval and should be finalised Mid July 2013.
- The benefit of this technology is that it not only compliments SUDA's current ArTiMist™ Project but it also provides a strong foundation for the development of other drug candidates which may open the doors to lucrative licensing agreements.

NovaMist™

- The NovaMist™ platform provides a valuable life cycle extension strategy for innovators whose products are facing patent expiration and new product development opportunities for companies wishing to develop their own brand of a competitor's drug that is approaching patent expiration.



- The key product in development, Duromist™, is a stable solution of lingual Sildenafil (the active ingredient in Viagra™) that has shown preliminary bioequivalence to Viagra™ tablets in early clinical trials. The Erectile Dysfunction market worldwide is \$4.1 billion and outside of the USA is approx. \$2billion pa

NovaMist™

- NovaDel's NovaMist™ technology may provide substantial potential benefits compared to other modes of drug administration including:
 - Faster onset of action
 - Lower dose
 - Enhanced patient compliance and convenience
 - Avoiding the need to swallow
 - Allowing medication to be taken without water
 - Increased bioavailability of drug by avoiding metabolism by liver

NovaMist™

- There are a number of products in various stages of development including.
- Note all the following products have shown good results in proof of concept studies.
 - sumatriptan, (worlds largest selling migraine drug) being developed for the treatment of migraine headache); (Phase 2/3)
 - Duromist™ (an oral spray formulation of sildenafil, being developed for the treatment of erectile dysfunction); (Phase 1/2)
 - Zensana™ (an oral spray formulation of odansetron, being developed for the treatment of chemotherapy-induced nausea and vomiting); (Phase 1/2)
 - NVD-101 (oral spray formulation of sildenafil being developed for the treatment of Pulmonary Arterial Hypertension) (Phase 1/2)
 - NVD-301 (an oral spray formulation of midazolam, being developed for sedation during diagnostic, therapeutic, and endoscopic procedures). (Pre-Clinical)

SUDA LTD

Product Pipeline



SUDA is progressing rapidly to commercialisation of the worlds first sub-lingual Malaria treatment for children.

SUDA LTD

Future milestones

Milestone	Expected time frame
ArTiMist™ Final Clinical trial Report	July 2013
Completion of NovaMist™ Acquisition	July 2013
Lodging of ArTiMist™ Regulatory File in first jurisdiction	December 2013 - January 2014
First NovaMist™ deal	March -April 2014
ArTiMist™ Trade Sale	February-August 2014

SUDA LTD

Our People

- **Stephen Carter. Chairman and Chief Executive Officer**
 - Has extensive pharmaceutical industry experience with multi-national pharmaceutical and listed public companies.
- **Michael Stewart. Non-Executive Director**
 - Broad corporate and management background and involvement in bilateral donor funded and World Bank co-financed Aid Projects
- **Ken Robson Non-Executive Director**
 - His background includes extensive experience as a Corporate Lawyer and Advisor, specialising in fundraising, market compliance and Mergers & Acquisitions.
- **Joseph Ohayon CFO and Director**
 - Has over 20 years' experience in financial roles including 12 years within health-related industries.

SUDA LTD

Corporate Information

ASX Code:	(ASX:SUD)
Market Capitalisation:	\$20 M
Number of Shares on Issue:	626,091,284
6 month high: 30/04/2013	\$0.049
6 month low: 16/11/2012	\$0.027
30 Day VWAP:	\$0.037
Average Trading Volume:	1.7M
Cash at 1st April 2013	\$1.3M

The background is a solid blue color with intricate white line art patterns. These patterns consist of various geometric shapes, including circles, ellipses, and intersecting lines, creating a complex, web-like structure. The lines are thin and vary in density, with some areas being more concentrated than others. The overall effect is a modern, technical, and artistic aesthetic.

SUDA LTD

Thank You